Fierce Pharma

JUNE 29, 2023

By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |

Sales 247

Sales 247

pharmaphorum

MAY 21, 2024

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

118

118

Fierce Pharma

JANUARY 24, 2023

Bayer’s oncology business looks to collect $10B in sales by 2030, exec says zbecker Tue, 01/24/2023 - 09:14

Sales 233

Sales 233

Fierce Pharma

FEBRUARY 9, 2023

Now, it plans 15 drug launches by 2030 aliu Thu, 02/09/2023 - 10:00 AstraZeneca met CEO Pascal Soriot's $40B revenue goal early.

246

246

pharmaphorum

MARCH 1, 2024

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.

129

129

Fierce Pharma

OCTOBER 2, 2023

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

Leads 167

Leads Sales Pharma 167

European Pharmaceutical Review

MARCH 28, 2024

billion by 2030. percent between 2024-2030. by 2030 appeared first on European Pharmaceutical Review. The global pharmaceutical and biotechnology environmental monitoring market valued $24 billion in 2023, according to a report by Verified Market Research. This figure is projected to increase to $38.1 PerkinElmer, Inc.

Marketing 98

Marketing Pharmaceutical Pharma Management 98

European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. percent between 2023 and 2030. percent from 2023 to 2030. The post HPLC market projected to value $8 million by 2030 appeared first on European Pharmaceutical Review. What is driving the HPLC market?

Marketing 98

Marketing Biopharma Pharmaceutical Pharma 98

European Pharmaceutical Review

JULY 18, 2023

billion by 2030. Digitalisation to boost quality management systems market The post QMS market to value nearly $4b by 2030 appeared first on European Pharmaceutical Review. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Marketing 98

Marketing Management Manufacturing Pharmaceutical manufacturing 98

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. billion by 2030 appeared first on European Pharmaceutical Review. According to a market report , the global RNA therapy clinical trials market is anticipated to reach $3.5

Marketing 98

Marketing Safety Pharmaceutical Medicine 98

Fierce Pharma

JUNE 7, 2024

With 25 launches planned through 2030, Boehringer Ingelheim is gearing up for a busy few years. | The launches are part of the company's wider plan to bring 25 new products to the market by 2030.

Marketing 236

Marketing 236

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Manufacturing 105

Manufacturing Pharma Pharmaceutical Marketing 105

Fierce Pharma

JUNE 13, 2024

Pfizer's oncology division plans to have eight blockbusters by 2030, with contributions from each of its four focused therapeutic areas.

284

284

MedCity News

FEBRUARY 17, 2023

For example, one said that healthcare will be close to establishing a value-based formulary by 2030, and another said that longitudinal patient tracking will become a more important part the drug pricing process. Panelists at a recent pharmacy conference were optimistic about the future of value-based drug contracting.

Healthcare 111

Healthcare Healthcare Patients Pharma 111

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Sales 96

Sales Pharma Government Medicine 96

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review. The global buccal drug delivery market is projected to grow from $3.38

Marketing 52

Marketing Management Patients Pharmaceutical 52

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Marketing 96

Marketing Pharmaceutical Manufacturing Pharma 96

Fierce Pharma

FEBRUARY 29, 2024

The company aims to have at least eight blockbuster cancer drugs by 2030, with a focus on four main cancer types.

71

71

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Manufacturing 98

Manufacturing Marketing Side effects Transportation 98

Fierce Pharma

JUNE 12, 2023

Bayer recently laid out its ambition | Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.

Sales goal 352

Sales goal Sales 352

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

Fierce Pharma

FEBRUARY 7, 2024

Overall, the company is pushing to generate 30% of its revenues from oncology by 2030. In 2023, the number was 11%.

271

271

Pharmaceutical Technology

JUNE 14, 2023

The recommendations to combat AMR propose that there should be a 20% reduction in the total human consumption of antibiotics by 2030 alongside an even larger pushback against their use in animals, per the 13 June announcement.

Sales 52

Sales Pharmaceutical 52

Medico Reach

SEPTEMBER 12, 2022

billion by 2030. Gastrointestinal Endoscopic Devices Market Growth (2022-2030) appeared first on MedicoReach. The demand for this procedure contributes significantly to the gastrointestinal endoscopic market size was valued at USD 12.6 billion in 2021. The market is further expected to grow at a rate of 9.4% The post U.S.

Marketing 52

Marketing Doctors Training Medical 52

pharmaphorum

DECEMBER 7, 2023

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

Sales 95

Sales 95

pharmaphorum

APRIL 16, 2024

Boehringer Ingelheim says the strongest R&D pipeline in its history is set to deliver 25 new product launches between now and 2030

116

116

Fierce Pharma

AUGUST 4, 2023

The company is sticking to its ambitions of pulling a third of its revenue from its oncology portfolio by 2030. For years, Gilead has been on a mission to become a power player in oncology. | This year, the company expects $3 billion to come from its cancer trio of Trodelvy, Tecartus and Yescarta.

130

130

PharmaVoice

MAY 23, 2024

Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.

Sales goal 52

Sales goal Sales Pharma 52

PharmaVoice

FEBRUARY 20, 2024

By 2030, the AI market is expected to reach $187.95 A significant growth is predicted for both AI and IoT in healthcare. billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

Healthcare 104

Healthcare Healthcare Marketing 104

Pharmaceutical Commerce

APRIL 17, 2024

A panel uncovers the value in meeting carbon-neutral goals by 2030.

105

105

Pharmaceutical Technology

SEPTEMBER 15, 2023

A new report found that the Remote Patient Monitoring (RPM) sector will grow, since the pandemic revealed the benefits of remote healthcare.

Patients 52

Patients Marketing Healthcare Healthcare 52

PharmExec

JANUARY 15, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Manufacturing 52

Manufacturing Marketing Pharmaceutical 52

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. percent between 2022-2030. Based on the research by Roots Analysis, it is expected to hold 37 percent of the market share by 2030.

Manufacturing 52

Manufacturing Pharmaceutical Marketing 52

Pharmaceutical Commerce

JANUARY 15, 2024

Roots Analysis report suggests increase can be attributed to the growing demand for advanced therapies and biologics.

Manufacturing 52

Manufacturing Marketing Pharmaceutical 52

European Pharmaceutical Review

FEBRUARY 2, 2024

Facilitated by more than 3,000m² of floor space at the site, Orano Med shared that it is aiming to produce ten times this quantity by the end of the 2030. The build of ATLab Valenciennes has been selected under the France 2030 plan. As a result, the project will receive public support of almost €3.8

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical 98

Pharmaceutical Technology

SEPTEMBER 6, 2023

AstraZeneca is working with its collaborators to ensure the changes are not just internal but across the entire chain footprint.

52

52

Pharmaceutical Technology

MAY 1, 2024

Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class that leading data and analytics company GlobalData forecasts will generate more than $45bn in revenue by 2030.

Leads 52

Leads 52